Precigen Shares Drop 25% Following Inovio's FDA Approval of Voceryq
Precigen shares experienced a significant decline of approximately 25% during Monday trading. This sell-off follows an announcement made after the market close on October 30 regarding regulatory developments in the immunotherapy sector. The downward pressure is attributed to the U.S. Food and Drug Administration (FDA) granting approval to Inovio Pharmaceuticals (INO) for its product, Voceryq. The treatment is indicated for patients suffering from recurrent respiratory papillomatosis, a rare disease.
Topics: biotechnology FDA approval stock price movement
Read the full article at Seeking Alpha
Part of the story Inovio Pharmaceuticals Shares Surge Following FDA Approval of Voceryq for RRP (2 articles)